Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, DHU Sight Restore.
CHNO des Quinze-Vingts, DHU Sight Restore, INSERM-DHOS CIC.
J Glaucoma. 2018 Dec;27(12):1105-1111. doi: 10.1097/IJG.0000000000001041.
The purpose of this study was to evaluate the effect of treating ocular surface disease (OSD) in patients with medically uncontrolled primary open-angle glaucoma (POAG) associated with OSD.
We compiled a retrospective observational case series of 10 patients with POAG that remained uncontrolled with topical treatments and who were referred for filtering glaucoma surgery. All patients underwent a complete assessment of their glaucoma and ocular surface for both eyes. The main treatments were change of topical antiglaucoma medications to preservative-free equivalents, removal of allergenic treatments or those identified as causing side effects, switch to another therapeutic class with the same efficacy but with a better safety profile and treatment of OSD.
After a minimum follow-up of 6 months, we observed improved ocular surface in all patients, associated with an intraocular pressure (IOP) decrease or stabilization even if some antiglaucoma medications were removed. The mean IOP significantly decreased from 23.75±9.98 mm Hg to 15.15±4.75 mm Hg (-36.2%; P=0.0001). The mean number of IOP-lowering medications was 3.7±1.06 at presentation and 2.8±0.63 after treatment (P=0.01). The Oxford score also decreased from a mean 1.7±0.67 to 0.4±0.51 (-76.5%; P<0.001). For 2 patients, IOP was not sufficiently reduced after treatment and they finally underwent filtering surgery.
The prevalence of OSD in POAG patients is very high, particularly in patients with uncontrolled glaucoma with multiple topical medications. Careful management of the ocular surface associated with a reduction of the toxicity of eyedrops may result in improvement of ocular surface health and better IOP control.
本研究旨在评估治疗伴有眼表疾病(OSD)的药物控制不良原发性开角型青光眼(POAG)患者的眼表疾病的效果。
我们汇编了 10 例 POAG 患者的回顾性观察性病例系列,这些患者因眼部表面疾病而无法用局部治疗控制,因此被转诊接受滤过性青光眼手术。所有患者均对双眼的青光眼和眼表进行了全面评估。主要治疗方法包括:将局部抗青光眼药物更换为不含防腐剂的等效药物,停用过敏原治疗或已确定有副作用的治疗方法,改用疗效相同但安全性更好的另一类治疗药物,并治疗眼表疾病。
在至少 6 个月的随访后,我们观察到所有患者的眼表均得到改善,眼压(IOP)降低或稳定,即使一些抗青光眼药物被停用。平均 IOP 从 23.75±9.98mmHg 显著降低至 15.15±4.75mmHg(下降 36.2%;P=0.0001)。就诊时平均使用 3.7±1.06 种降眼压药物,治疗后降至 2.8±0.63 种(P=0.01)。牛津评分也从平均 1.7±0.67 降至 0.4±0.51(下降 76.5%;P<0.001)。对于 2 例患者,治疗后眼压仍未充分降低,最终接受了滤过性手术。
POAG 患者的 OSD 患病率非常高,特别是在伴有多种局部药物治疗的未控制青光眼患者中。仔细管理眼表并减少滴眼剂的毒性可能会改善眼表健康状况并更好地控制眼压。